A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Clinical trial NCT04024462 · COMPLETED
Trial details
- NCT number
- NCT04024462
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-05
- Primary completion
- 2021-12-13
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.